nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2021-2-117-122nnp-1550Research ArticleREVIEWSОБЗОРЫDrug-induced hypersomniaЛекарственно-индуцированная гиперсомнияОстроумоваТ. М.OstroumovaT. M.

 Россия, 119991, Москва, ул. Трубецкая, 8, стр. 2 

 8, Trubetskaya Str., Build. 2, Moscow 119991, Russia 

t.ostroumova3@gmail.comОстроумоваО. Д.OstroumovaO. D.

 Россия, 119991, Москва, ул. Трубецкая, 8, стр. 2 

 Россия, 125993, Москва, ул. Баррикадная, 2/1, стр. 1 

 8, Trubetskaya Str., Build. 2, Moscow 119991, Russia 

 2/1, Barrikadnaya Str., Build. 1, Moscow 125993, Russia 

ФилипповаА. В.FilippovaA. V.

 

 2/1, Barrikadnaya Str., Build. 1, Moscow 125993, Russia 

ГусеваТ. Ф.GusevaT. F.

 Россия, 127473, Москва, ул. Делегатская, 20, стр.1 

 20, Delegatskaya Str., Build. 1, Moscow 127473, Russia 

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет); ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава РоссииРоссияA.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of RussiaRussian Federation202123042021132117122Copyright © Ostroumova T.M., Ostroumova O.D., Filippova A.V., Guseva T.F., 20212021Остроумова Т.М., Остроумова О.Д., Филиппова А.В., Гусева Т.Ф.Ostroumova T.M., Ostroumova O.D., Filippova A.V., Guseva T.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1550

 Daytime somnolence may be a symptom of different somatic,  neurological and psychiatric diseases and develop due to abuse  and/or discontinuation of various medications. Drug- induced hypersomnia (DIH) is defined as hypersomnolence  caused by the intake of multiple drugs. DIH is one of the most frequently reported effects and/or side effects of drugs. DIH  prevalence varies widely and can be as high as 75% in patients receiving specific medications. DIH risk factors include elderly  and senile age, impaired drug metabolism, serum drug  concentration, method and frequency of drug administration, single and daily doses of drugs, etc., as in many other drug- induced diseases and syndromes. DIH can occur both due to sedative agents administration and withdrawal of  psychostimulants and other activating psychotropic  medications. Most often, the development of DIH is associated with the use of levodopa-carbidopa, antipsychotics,  antidepressants. The pathogenesis of DIH is complex and multifactorial and is associated with the mechanism of action of  individual drugs and the presence of concomitant diseases. The  article discusses the risk assessment of DIH development due to  various medications, diagnosis and management tactics of  patients with DIH.  

 Дневная сонливость может быть проявлением различных  соматических, неврологических и психических заболеваний, а также  развиваться при злоупотреблении и/или отмене различных  лекарственных средств (ЛС). Вызванная приемом ЛС дневная  сонливость расценивается как лекарственно-индуцированная гиперсомния (ЛИГ). ЛИГ относятся к числу наиболее часто регистрируемых эффектов и/или побочных эффектов ЛС. Распространенность ЛИГ варьирует в широких пределах и может достигать 75% на фоне применения отдельных препаратов. Факторы риска ЛИГ, как и при многих других лекарственно-индуцированных заболеваниях и синдромах, включают пожилой и старческий возраст, нарушение метаболизма ЛС, концентрацию ЛС в сыворотке крови, способ и кратность введения ЛС, разовые и суточные дозы ЛС и др. ЛИГ могут возникать как на фоне приема ЛС, вызывающих седацию, так и на фоне отмены психостимуляторов и других активирующих психотропных  ЛС. Наиболее часто развитие ЛИГ ассоциировано с  приемом леводопы-карбидопы, антипсихотиков, антидепрессантов.  Патогенез ЛИГ сложен, связан с многими факторами, механизмом действия отдельных ЛС и наличием сопутствующих заболеваний. В статье обсуждаются оценка риска развития ЛИГ на фоне различных ЛС, диагностика и тактика ведения подобных пациентов. 

гиперсомниялекарственно-индуцированная гиперсомниялекарственные средстванежелательные лекарственные реакциипобочные эффектыhypersomniadrug-induced hypersomniamedicationadverse drug reactionside effectsReferencesSateia MJ. International classification of sleep disorders – third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-94. doi: 10.1378/chest.14-0970Sateia MJ. International classification of sleep disorders – third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-94. doi: 10.1378/chest.14-0970Полуэктов МГ. Диагностика и лечение расстройств сна. Москва; 2016. С. 193-7.Poluektov MG. Diagnostika i lechenie rasstroystv sna [Diagnosis and treatment of sleep disorders]. Moscow; 2016. P. 193-7 (In Russ.).Gupta R, Seithikurippu R, Almeneessier A, et al. Hypersomnolence and Traffic Safety. Sleep Med Clin. 2017 Sep;12(3):489-99. doi: 10.1016/j.jsmc.2017.03.018. Epub 2017 Jun 8.Gupta R, Seithikurippu R, Almeneessier A, et al. Hypersomnolence and Traffic Safety. Sleep Med Clin. 2017 Sep;12(3):489-99. doi: 10.1016/j.jsmc.2017.03.018. Epub 2017 Jun 8.Pagel JF. Drug-Induced Hypersomnolence. Sleep Med Clin. 2017 Sep;12(3):383-93. doi: 10.1016/j.jsmc.2017.03.011. Epub 2017 Jun 10.Pagel JF. Drug-Induced Hypersomnolence. Sleep Med Clin. 2017 Sep;12(3):383-93. doi: 10.1016/j.jsmc.2017.03.011. Epub 2017 Jun 10.Gastel AV. Drug-Induced Insomnia and Excessive Sleepiness. Sleep Med Clin. 2018 Jun;13(2):147-59. doi: 10.1016/j.jsmc.2018.02.001. Epub 2018 Mar 28.Gastel AV. Drug-Induced Insomnia and Excessive Sleepiness. Sleep Med Clin. 2018 Jun;13(2):147-59. doi: 10.1016/j.jsmc.2018.02.001. Epub 2018 Mar 28.Pagel JF, Pandi-Perumal SR, editors. Primary Care Sleep Medicine: A Practical Guide. New York: Springer; 2014. doi: 10.1007/978-1-4939-1185-1Pagel JF, Pandi-Perumal SR, editors. Primary Care Sleep Medicine: A Practical Guide. New York: Springer; 2014. doi: 10.1007/978-1-4939-1185-1Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.Dauvilliers Y, Buguet A. Hypersomnia. Dialogues Clin Neurosci. 2005;7(4):347-56. doi: 10.31887/DCNS.2005.7.4/ydauvilliersDauvilliers Y, Buguet A. Hypersomnia. Dialogues Clin Neurosci. 2005;7(4):347-56. doi: 10.31887/DCNS.2005.7.4/ydauvilliersHolm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. doi: 10.2165/00003495-200059040-00014Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. doi: 10.2165/00003495-200059040-00014Drakatos P, Marples L, Muza R, et al. NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients. Sleep Med. 2019 Jan;53:181-8. doi: 10.1016/j.sleep.2018.03.021. Epub 2018 Apr 10.Drakatos P, Marples L, Muza R, et al. NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients. Sleep Med. 2019 Jan;53:181-8. doi: 10.1016/j.sleep.2018.03.021. Epub 2018 Apr 10.Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009138. doi: 10.1002/14651858.CD009138.pub2Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009138. doi: 10.1002/14651858.CD009138.pub2Katona CL, Hunter BN, Bray J. A doubleblind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998 Feb;13(2):100-8. doi: 10.1002/(sici)1099-1166(199802)13:2<100::aid-gps738>3.0.co;2-jKatona CL, Hunter BN, Bray J. A doubleblind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998 Feb;13(2):100-8. doi: 10.1002/(sici)1099-1166(199802)13:2<100::aid-gps738>3.0.co;2-jFagiolini A, Albert U, Ferrando L, et al. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol. 2020 May;35(3):137-46. doi: 10.1097/YIC.0000000000000304Fagiolini A, Albert U, Ferrando L, et al. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol. 2020 May;35(3):137-46. doi: 10.1097/YIC.0000000000000304Rizo C, Deshpande A, Ing A, et al. A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. J Affect Disord. 2011 Apr;130(1-2):290-3. doi: 10.1016/j.jad.2010.07.027. Epub 2010 Aug 12.Rizo C, Deshpande A, Ing A, et al. A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. J Affect Disord. 2011 Apr;130(1-2):290-3. doi: 10.1016/j.jad.2010.07.027. Epub 2010 Aug 12.Schweitzer PK, Griffin KS. Hypersomnia due to Medication or Substance. In: Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier; 2017. doi: 10.1016/b978-0-12-809324-5.01065-8Schweitzer PK, Griffin KS. Hypersomnia due to Medication or Substance. In: Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier; 2017. doi: 10.1016/b978-Crocco EA, Cruz-Ortiz С, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psych. 2017 Mar;4(1):33-46. doi: 10.1007/s40501-017-0102-4. Epub 2017 Feb 10.0-12-809324-5.01065-8Miller DD, Pharm D. Atypical Antipsychotics: Sleep, Sedation, and Efficacy. Prim Care Companion. J Clin Psychiatry. 2004;6(Suppl 2):3-7.Crocco EA, Cruz-Ortiz С, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psych. 2017 Mar;4(1):33-46. doi: 10.1007/s40501-017-0102-4. Epub 2017 Feb 10.Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.Miller DD, Pharm D. Atypical Antipsychotics: Sleep, Sedation, and Efficacy. Prim Care Companion. J Clin Psychiatry. 2004;6(Suppl 2):3-7.Elger CE, Stefan H, Mann A, at al. A 24-week multicenter, randomized, doubleblind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010 Feb;88(2-3):255-63. doi: 10.1016/j.eplepsyres.2009.12.003. Epub 2010 Jan 12.Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.Bonanni E, Galli R, Maestri M, et al. Daytime Sleepiness in Epilepsy Patients Receiving Topiramate Monotherapy. Epilepsia. 2004 Apr;45(4):333-7. doi: 10.1111/j.0013-9580.2004.47803.xElger CE, Stefan H, Mann A, at al. A 24-week multicenter, randomized, doubleblind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010 Feb;88(2-3):255-63. doi: 10.1016/j.eplepsyres.2009.12.003. Epub 2010 Jan 12.Reife R, Pledger G, Wu S. Topiramate as Add-On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults. Epilepsia. 2000;41(S1):66-71. doi: 10.1111/j.1528-1157.2000.tb02175.xBonanni E, Galli R, Maestri M, et al. Daytime Sleepiness in Epilepsy Patients Receiving Topiramate Monotherapy. Epilepsia. 2004 Apr;45(4):333-7. doi: 10.1111/j.0013-9580.2004.47803.xBiton V, Krauss G, Vasquez-Santana B, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011 Feb;52(2):234-42. doi: 10.1111/j.1528-1167.2010.02729.x. Epub 2010 Sep 30.Reife R, Pledger G, Wu S. Topiramate as Add-On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults. Epilepsia. 2000;41(S1):66-71. doi: 10.1111/j.1528-1157.2000.tb02175.xНодель МР. Гиперсомния и циркадные нарушения при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2016;8(4):45-50. doi: 10.14412/2074-2711-2016-4-45-50Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011 Feb;52(2):234-42. doi: 10.1111/j.1528-1167.2010.02729.x. Epub 2010 Sep 30.Левин ОС, Ляшенко ЕА. Нарушения сна при болезни Паркинсона. Фарматека. 2014;10(3):12-9.Nodel MP. Hypersomnia and circadian disturbances in Parkinson’s disease. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):45-50. doi: 10.14412/2074-2711-2016-4-45-50 (In Russ.).Schweitzer PK, Randazzo AC. Drugs that disturb sleep and wakefulness. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. Philadelphia: Elsevier; 2017. P. 480-98.Levin OS, Lyashenko EA. Sleep disturbances in Parkinson's disease. Farmateka = Pharmateca. 2014;10(3):12-9 (In Russ.).Rosen G, Harris AK, Liu M, et al. The effects of Dexamethasone on sleep in young children with Acute Lymphoblastic Leukemia. Sleep Med. 2015 Apr;16(4):503-9. doi: 10.1016/j.sleep.2014.11.002. Epub 2015 Feb 2.Schweitzer PK, Randazzo AC. Drugs that disturb sleep and wakefulness. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. Philadelphia: Elsevier; 2017. P. 480-98.Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540Rosen G, Harris AK, Liu M, et al. The effects of Dexamethasone on sleep in young children with Acute Lymphoblastic Leukemia. Sleep Med. 2015 Apr;16(4):503-9. doi: 10.1016/j.sleep.2014.11.002. Epub 2015 Feb 2.Gros P, Videnovic A. Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease. Clin Geriatr Med. 2020 Feb;36(1):119-30. doi: 10.1016/j.cger.2019.09.005. Epub 2019 Sep 6.Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540Сычев ДА, Остроумова ОД, Переверзев АП и др. Лекарственные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020; (6):113-26. doi: 10.18565/pharmateca.2020.6.113-126Gros P, Videnovic A. Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease. Clin Geriatr Med. 2020 Feb;36(1):119-30. doi: 10.1016/j.cger.2019.09.005. Epub 2019 Sep 6.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Greenblatt Clin Pharmacol. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Farmakonadzor. Farmateka = Pharmacovigilance. Pharmateca. 2020;(6):113-26. doi: 10.18565/pharmateca.2020.6.113-126 (In Russ.).Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Greenblatt Clin Pharmacol. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Greenblatt Clin Pharmacol. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154

The authors declare that there are no conflicts of interest present.